The global plasma fractionation market size was valued at USD 33.43 billion in 2024 and is anticipated to grow from USD 36.18 billion in 2025 to reach USD 67.96 billion in 2033, growing at a CAGR of 8.2% during the forecast period (2025–2033). The growth of the market is attributed to improved research and development (r&d), growing geriatric population, increased use of immunoglobulins and rising adoption of pdmps.

Market Scope and Research Methodology

This report includes a multi-level regional assessment spanning global, regional, and country-specific markets. The analysis highlights market penetration, regional market leadership, and the strategic approaches adopted by prominent companies. A detailed SWOT analysis identifies the strengths, weaknesses, opportunities, and challenges within the market.

The primary goal of the Plasma Fractionation Market Report is to provide clear insights into market behavior, emerging trends, and the factors influencing market performance. The study evaluates market structure, segmentation, and forecasted market size while examining growth drivers, industry barriers, and opportunities stemming from technological progress, regulatory frameworks, cost efficiencies, and evolving consumer needs.

Download Exclusive Research Report PDF Sample: (Including Full TOC, List of Tables & Figures, Chart): https://straitsresearch.com/report/plasma-fractionation-market/request-sample

Regional Insights

The report presents an in-depth regional assessment of the Plasma Fractionation Market across North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Each region is analyzed based on key parameters such as market size, growth rate, trade activities, and overall industry development. This segmentation supports a deeper understanding of the competitive dynamics and market potential within each geographical area.

Market Segmentation

1. By Product
   1. Albumin
   2. Immunoglobulins
      1. Intravenous immunoglobulins
      2. Subcutaneous immunoglobulins
      3. Others
   3. Coagulation Factors
      1. Factor VIII
      2. Factor IX
      3. Von Willebrand Factor
      4. Prothrombin Complex Concentrates
      5. Fibrinogen Concentrates
      6. Others
   4. Protease Inhibitors
   5. Others
2. By Method
   1. Centrifugation
   2. Depth Filtration
   3. Chromatography
   4. Others
3. By Application
   1. Neurology
   2. Hematology
   3. Oncology
   4. Immunology
   5. Pulmonology
   6. Others
4. By End Use
   1. Hospitals & Clinics
   2. Clinical Research
   3. Others

Key Market Players

1. Grifols S.A.
2. CSL Limited
3. Takeda Pharmaceutical Company Limited
4. Octapharma AG
5. Kedrion S.p.A
6. LFB S.A.
7. Biotest AG
8. Sanquin
9. Bio Products Laboratory Ltd.
10. Intas Pharmaceuticals Ltd.
11. Grifols, S.A.
12. ADMA Biologics
13. China Biologic Products Holdings Inc.
14. GC Pharma
15. Hualan Bioengineering Co., Ltd.

Download Exclusive Research Report PDF Sample: (Including Full TOC, List of Tables & Figures, Chart): https://straitsresearch.com/report/plasma-fractionation-market/request-sample

Key Questions Addressed

• What is Plasma Fractionation Market?
• What was the market size of the Plasma Fractionation Market in 2024?
• What CAGR is expected for the market during the forecast period?
• Which factors are expected to drive market growth?
• What are the major segments of the market?
• Which strategies are companies adopting to strengthen their market presence?
• What emerging applications and trends are shaping the industry?
• Who are the key players in the Plasma Fractionation Market?
• What are the portfolios and competencies of leading market participants?

About Us

For over a decade, Straits Research has been a trusted partner to more than 2,381 small and large enterprises, empowering senior leaders and decision-makers with actionable intelligence to navigate complex markets. Our structured syndicate reports, published year-round, cover critical sectors such as chemicals, materials, food and beverage, healthcare, pharmaceuticals, automotive, technology, aerospace, and defense. Combined with our custom research tailored to client-specific needs, we deliver insights that drive business progress and informed decision-making.